This site is intended for US Healthcare Professionals only.

ADC Therapeutics Congress Data Presentations

Browse through posters and presentations and learn about upcoming congress dates.

Filter by:Clear All
Filter by Congress, Product, and Year
Display upcoming events
Congress
Product/compound
Year
ASH 2021 | Dec 11–14, 2021
American Society of Hematology (ASH)
United States
DownloadCheck back for materials after the event
ISPOR EU 2021 | Dec 1–3, 2021
International Society for Pharmacoeconomics & Outcomes Research (ISPOR EU)
Virtual
DownloadCheck back for materials after the event
SITC 2021 | Nov 10–14, 2021
Society for Immunotherapy of Cancer (SITC)
Washington, D.C.
DownloadCheck back for materials after the event
AMCP Nexus 2021 | Oct 19–22, 2021
Academy of Managed Care Pharmacy (AMCP Nexus)
Denver, CO
DownloadCheck back for materials after the event
ESMO 2021 | POSTERSep 17–21, 2021
European Society for Medical Oncology (ESMO)
Paris, France
DownloadCheck back for materials after the event
ACCP 2021 | POSTERSep 12–14, 2021
American College of Clinical Pharmacy (ACCP)
Phoenix, AZ
DownloadCheck back for materials after the event
SOHO 2021 | POSTERSep 8–11, 2021
Incidence, onset, and management of edema and effusion in patients treated with loncastuximab tesirine for R/R DLBCL in the LOTIS clinical trial program
DownloadCheck back for materials after the event
SOHO 2021 | POSTERSep 8–11, 2021
LOTIS-2 follow-up analysis: Updated results from a Phase 2 study of loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma
DownloadCheck back for materials after the event
SOHO 2021 | POSTERSep 8–11, 2021
LOTIS-2 follow-up analysis: Updated results from a Phase 2 study of loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma
DownloadCheck back for materials after the event
SOHO 2021 | POSTERSep 8–11, 2021
Incidence, onset, and management of myelosuppression in patients treated with loncastuximab tesirine for R/R DLBCL in a pooled safety analysis
DownloadCheck back for materials after the event
SOHO 2021 | POSTERSep 8–11, 2021
Clinical activity of loncastuximab tesirine plus ibrutinib in non-Hodgkin lymphoma: Updated LOTIS-3 Phase 1 results
DownloadCheck back for materials after the event
ICML 2021 | POSTERJun 18–22, 2021
A Phase 2 randomized study of loncastuximab tesirine (Lonca) vs idelalisib in patients with relapsed or refractory (R/R) follicular lymphoma (FL) — LOTIS-6
DownloadCheck back for materials after the event
ICML 2021 | POSTERJun 18–22, 2021
A Phase 3 randomized study of loncastuximab tesirine plus rituximab vs immunochemotherapy in patients with relapsed/refractory diffuse large B-cell lymphoma — LOTIS-5
DownloadCheck back for materials after the event
ICML 2021 | POSTERJun 18–22, 2021
Clinical activity of loncastuximab tesirine plus ibrutinib in non-Hodgkin lymphoma: Updated LOTIS-3 Phase 1 results
DownloadCheck back for materials after the event
ICML 2021 | POSTERJun 18–22, 2021
LOTIS-2 follow-up analysis: Updated results from a Phase 2 study of loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma
DownloadCheck back for materials after the event
ICML 2021 | POSTERJun 18–22, 2021
Camidanlumab tesirine efficacy and safety in an open-label, multicenter, Phase 2 study of patients with relapsed or refractory classical Hodgkin lymphoma (R/R cHL)
DownloadCheck back for materials after the event
EHA 2021 | POSTERJun 10–13, 2021
European Hematology Association (EHA)
Vienna, Austria
DownloadCheck back for materials after the event
ASCO 2021 | POSTERJun 4–8, 2021
Phase 3 Randomized Study of Lonca plus Rituximab versus Immunochemotherapy in Patients with RR DLBCL LOTIS
DownloadCheck back for materials after the event
ASCO 2021 | POSTERJun 4–8, 2021
Duration of Response to Lonca RR DLBCL by Demographic Subgroup Analysis from LOTIS
DownloadCheck back for materials after the event
ISPOR 2021 | POSTERMay 15–19, 2021
International Society for Pharmacoeconomics & Outcomes Research (ISPOR)
Montreal, QC, Canada
DownloadCheck back for materials after the event
ASH 2020 | POSTERDec 5–8, 2020
Interim Results of Loncastuximab Tesirine Combined With Ibrutinib in Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma (LOTIS-3)
DownloadCheck back for materials after the event
ASH 2020 | POSTERDec 5–8, 2020
Efficacy and Safety of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
DownloadCheck back for materials after the event
ASH 2020 | POSTERDec 5–8, 2020
Safety and Antitumor Activity Study Evaluating Loncastuximab Tesirine and Rituximab Versus Immunochemotherapy in Diffuse Large B-Cell Lymphoma
DownloadCheck back for materials after the event
ASH 2020 | POSTERDec 5–8, 2020
Analysis of ADCT-602 Pre-Clinical Activity in B-Cell Lymphoma Models and Identification of Potential Biomarkers for Its Activity
DownloadCheck back for materials after the event
ASH 2020 | POSTERDec 5–8, 2020
Preliminary Results of a Phase 2 Study of Camidanlumab Tesirine (Cami), a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Patients With Relapsed or Refractory Hodgkin Lymphoma
DownloadCheck back for materials after the event
ASH 2020 | POSTERDec 5–8, 2020
Combination of Camidanlumab Tesirine, a CD25-Targeted ADC, with Gemcitabine Elicits Synergistic Anti-Tumor Activity in Preclinical Tumor Models
DownloadCheck back for materials after the event
ASH 2020 | POSTERDec 5–8, 2020
Pharmacokinetic and Pharmacodynamic Correlates From the Phase 1 Study of Camidanlumab Tesirine (Cami) in Patients With Relapsed or Refractory Hodgkin Lymphoma and Non-Hodgkin Lymphoma
DownloadCheck back for materials after the event
ESMO 2020 | POSTERSep 19–21, 2020
First-in-Human Study of Camidanlumab Tesirine (ADCT-301, Cami), an anti-CD25 Targeted Therapy in Patients (Pts) with Advanced Solid Tumors: Pharmacokinetics (PK) and Biomarker Evaluation
DownloadCheck back for materials after the event
EHA 2020 | PRESENTATIONJun 11–21, 2020
Initial Results of a Phase 2 Study of Loncastuximab Tesirine, a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
DownloadCheck back for materials after the event
EHA 2020 | POSTERJun 11–21, 2020
Interim Results of a Phase 1/2 Study of Loncastuximab Tesirine (Lonca) Combined with Ibrutinib in Advanced Diffuse Large B-Cell Lymphoma (DLBCL) or Mantle Cell Lymphoma (MCL)
DownloadCheck back for materials after the event
ASH 2019 | PRESENTATIONDec 7–10, 2019
Interim Futility Analysis of a Phase 2 Study of Loncastuximab Tesirine, a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
DownloadCheck back for materials after the event
ESMO 2019 | POSTERSep 27–Oct 1, 2019
A Phase 1, Open-label, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-601 in Patients with Advanced Solid Tumors
DownloadCheck back for materials after the event
ICML 2019 | PRESENTATIONJun 18–23, 2019
Analysis of Efficacy and Safety of Loncastuximab Tesirine (ADCT-402) by Demographic and Clinical Characteristics in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
DownloadCheck back for materials after the event
ICML 2019 | PRESENTATIONJun 18–23, 2019
The Antibody-Drug Conjugate (ADC) Loncastuximab Tesirine (ADCT 402) Targeting CD19 Shows Strong in vitro Anti-Lymphoma Activity Both As Single Agents and in Combination
DownloadCheck back for materials after the event
ICML 2019 | PRESENTATIONJun 18–23, 2019
Analysis of Clinical Determinants Driving Safety and Efficacy of Camidanlumab Tesirine (ADCT-301, Cami) in Relapsed/Refractory (R/R) Classical Hodgkin Lymphoma (cHL)
DownloadCheck back for materials after the event
ICML 2019 | POSTERJun 18–23, 2019
The anti-CD25 antibody-drug conjugate camidanlumab tesirine (ADCT-301) presents a strong preclinical activity both as single agent and in combination in lymphoma cell lines
DownloadCheck back for materials after the event
ASH 2018 | PRESENTATIONDec 1–4, 2018
Phase 1 Study of ADCT-301 (Camidanlumab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate, in Relapsed/Refractory Classical Hodgkin Lymphoma
DownloadCheck back for materials after the event
SITC 2018 | POSTERNov 9–11, 2018
A CD25-targeted pyrrolobenzodiazepine dimer-based antibody-drug conjugate shows potent anti-tumor activity in pre-clinical models of solid tumors either alone or in combination with a PD-1 inhibitor
DownloadCheck back for materials after the event
AACR 2018 | POSTERApr 14–18, 2018
Pre-clinical activity of ADCT-601, a novel pyrrolobenzodiazepine (PBD) dimer-based antibody-drug conjugate (ADC) targeting AXL-expressing tumors
DownloadCheck back for materials after the event
AACR 2018 | POSTERApr 14–18, 2018
ADCT-701, a novel pyrrolobenzodiazepine (PBD) dimer-based antibody-drug conjugate (ADC) targeting DLK1-expressing tumors
DownloadCheck back for materials after the event
ASH 2017 | POSTERDec 9–12, 2017
Elucidating Exposure-Response (Safety and Efficacy) of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Containing Antibody Drug Conjugate, for Recommended Phase 2 Dose Determination in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma
DownloadCheck back for materials after the event
ASH 2017 | POSTERDec 9–12, 2017
Results from an Ongoing Phase 1 Study Indicate ADCT-301 (Camidanlumab Tesirine) Is Well Tolerated in Patients with Relapsed or Refractory CD25-Positive Acute Leukemia
DownloadCheck back for materials after the event
AACR 2017 | POSTERApr 1–5, 2017
Characterization of the mechanism of action, pharmacodynamics and preclinical safety of ADCT-402, no. 51 a pyrrolobenzodiazepine (PBD) dimer-containing antibody-drug conjugate (ADC) targeting CD19-expressing hematological malignancies
DownloadCheck back for materials after the event
ASH 2016 | POSTERDec 3–6, 2016
ADCT-602 (hLL2-cys-PBD), a new site-specifically conjugated, pyrrolobenzodiazepine (PBD) dimer-based antibody drug conjugate (ADC) targeting CD22-expressing B-cell malignancies
DownloadCheck back for materials after the event
ASCO 2016 | POSTERJun 3–7, 2016
A phase 1 dose-escalation study to evaluate the tolerability, safety, pharmacokinetics, and antitumor activity of ADCT-402 in patients with relapsed or refractory B-cell lineage non-Hodgkin lymphoma (B-NHL)
DownloadCheck back for materials after the event
AACR 2015 | POSTERApr 18–22, 2015
Pre-clinical Activity of hLL2-PBD, a Novel Anti-CD22 Antibody-Pyrrolobenzodiazepine (PBD) Conjugate in Models of Non-Hodgkin Lymphoma
DownloadCheck back for materials after the event
Use the filters to view congress data presentations.
Use the filters to view congress data presentations.

Contact ADC Therapeutics

Report Adverse Reactions or Product Complaints

To report suspected adverse events or product complaints, please call us at 1-855-690-0340 and select prompt 1. You may also call the FDA at 1-800-FDA-1088 or report suspected adverse events at www.fda.gov/medwatch.